Alydia offers the Jada system to support normal contraction of the uterus to stop excessive bleeding after childbirth
Global healthcare company Organon has completed the acquisition of commercial-stage medical device firm Alydia Health for $240m.
The deal included a $215m cash payment and a $25m contingent milestone payment.
Alydia Health, which was established in 2010, primarily focuses on the prevention of maternal morbidity and mortality caused by postpartum hemorrhage (PPH) or abnormal postpartum uterine bleeding.
Postpartum hemorrhage, which is a general complication of birth, needs pharmacologic treatment in up to 10% of mothers and may result in an emergency intervention such as hysterectomy and blood transfusions.
Alydia Health CEO Rob Binney said: “Alydia Health is thrilled to be joining a company that can help progress our founding vision through its commitment to listen to women, to understand her health needs and to bring forward more options.”
Alydia has designed the Jada System, which will enable normal contraction of the uterus to stop excessive bleeding after childbirth.
In August last year, the company secured 510(k) clearance from the US Food and Drug Administration (FDA) for the Jada system based on data from the pivotal PEARLE IDE study.
Earlier this month, Organon announced the launch of a new company to meet women’s everyday health requirements. It mainly focuses on reproductive health and health issues that affect women.
Organon CEO Kevin Ali said: “Organon’s acquisition of Alydia Health expands our portfolio into the medical device category and underscores our commitment to identify options for women’s unmet medical needs.
“This acquisition brings us one step closer to our vision of a better and healthier every day for every woman around the world.”
Organon, a spinoff from Merck, provides a portfolio of over 60 medicines and products across a range of therapeutic areas.